original ) (raw )Effect of Direct Renin Inhibition on Renal Hemodynamic Function, Arterial Stiffness, and Endothelial Function in Humans With Uncomplicated Type 1 Diabetes: A pilot study
Vesta Lai
Diabetes Care, 2010
View PDFchevron_right
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria
Antonino Saitta
Journal of the Renin-Angiotensin-Aldosterone System, 2014
View PDFchevron_right
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)
Frederik Persson
Journal of the Renin-Angiotensin-Aldosterone System, 2012
View PDFchevron_right
patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in of Renin-Angiotensin-Aldosterone System Additional services and information for
Antonino Saitta
Journal of Renin-Angiotensin-Aldosterone System
View PDFchevron_right
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Jorge Polonia
New England Journal of Medicine, 2012
View PDFchevron_right
Blockade of the renin-angiotensin system for the primary prevention of diabetic
Robert Macginley
2012
View PDFchevron_right
ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus
Radomir Stevanovic
Kidney International, 2005
View PDFchevron_right
Renoprotective effect of aliskiren monotherapy and aliskiren−pentoxifylline combination in hypertensive-diabetic type 2 patients with diabetic nephropathy
Mohammed Taha
Bulletin of Faculty of Pharmacy, Cairo University, 2013
View PDFchevron_right
Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria
Frederik Persson
Diabetes Care, 2009
View PDFchevron_right
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Hans-henrik Parving
New England Journal of Medicine, 2008
View PDFchevron_right
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy
Kasper Rossing
Nephrology Dialysis Transplantation, 2002
View PDFchevron_right
Safety of enhanced renin–angiotensin–aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease
Przemysław Rutkowski
Polish Archives of Internal Medicine, 2013
View PDFchevron_right
Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
Vjekoslav Gerc
Medical Archives, 2009
View PDFchevron_right
Blockade of the renin–angiotensin system for the primary prevention of diabetic nephropathy
Robert Macginley
Diabetes management, 2012
View PDFchevron_right
Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes
Terezie Pelikanova
Journal of the renin-angiotensin-aldosterone system : JRAAS, 2004
View PDFchevron_right
Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats
Yinong Zhou
View PDFchevron_right
Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes
Frederik Persson
Kidney International, 2008
View PDFchevron_right
Autonomy of the Renin System In Type II Diabetes Mellitus: Dietary Sodium and Renal Hemodynamic Responses to ACE Inhibition
Jose Mario de Oliveira
Kidney …, 1997
View PDFchevron_right
Pleiotropic effects of inhibitors of the RAAS in the diabetic population: Above and beyond blood pressure lowering
Amgad Makaryus
Current Diabetes Reports, 2010
View PDFchevron_right
diabetes Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1
Terezie Pelikanova
2000
View PDFchevron_right
Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension
William Dole
Journal of The American Society of Hypertension, 2017
View PDFchevron_right
Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Brian Tomlinson
Current Diabetes Reviews, 2008
View PDFchevron_right
Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents
Paolo Verdecchia
Hypertension Research, 2011
View PDFchevron_right
Arterial stiffness and haemodynamic response to vasoactive medication in subjects with insulin-resistance syndrome
Anthony O'Sullivan
Clinical Science, 2008
View PDFchevron_right
Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers
Pauline Swift
Journal of the renin-angiotensin-aldosterone system : JRAAS, 2001
View PDFchevron_right
The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes
Ronnie Har
Diabetologia, 2013
View PDFchevron_right
Renal and Hormonal Responses to Direct Renin Inhibition With Aliskiren in Healthy Humans
William Dole
Circulation, 2008
View PDFchevron_right
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy
oguz Cakir
Nephrology, 2010
View PDFchevron_right
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy
Kasper Rossing
Kidney International, 2003
View PDFchevron_right
Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
G. Boner
Annals of Pharmacotherapy, 2004
View PDFchevron_right
Renin inhibitors in diabetes and hypertension: an update
Yagiz Uresin
EXCLI Journal, 2014
View PDFchevron_right